At the news
? NEUTRALIMPACT 4/10 8-K filed Apr 13, 2026 at 08:30 ET
Septerna announced the initiation of Phase 1 clinical trials for its oral PTH1R agonist SEP-479 for hypoparathyroidism, with data expected in late 2026 or early 2027. The company also provided updates on its other clinical programs including SEP-631 and its collaboration with Novo Nordisk, while highlighting its cash runway into 2029.
- Company initiated Phase 1 clinical trial for SEP-479, an oral PTH1R agonist for hypoparathyroidism
- Phase 1 trial is a single-ascending dose (SAD) and multiple-ascending dose (MAD) study in healthy volunteers
- Data from the trial is anticipated in late 2026 or early 2027
- SEP-631 Phase 1 study demonstrated robust pharmacodynamics with QD dosing
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access